Prevalence estimates of COPD are as high as 11.4% to 26.1% for the population older than 40 years. The Global burden of disease study 2010 showed that COPD is the 3rd leading cause of death and the 9th cause of DALYs worldwide. There are many pharmacological and non-pharmacological treatment options. iMTA has done trial-based, model-based as well as real-world economic evaluations of: medication (e.g. POET trial, BRONCUS trial), pulmonary rehabilitation (e.g. INTERCOM trial), nutritional counselling and supplements (NUTRAIN trial), integrated care (e.g. RECODE trial), smoking cessation, early assisted discharge (GO-AHEAD trial), etc.
iMTA has also done many methodological studies on COPD cost effectiviness like a DCE on home versus hospital care, a DCE on components of the burden of disease, utility measurement of COPD health profiles, algorithms to adjust for COPD severity in real-world studies, estimation of the case-fatality of COPD-exacerbations, investigating the ability of the new GOLD classification to predict mortality, exacerbation and lung funtion declince, etc.